Lonaprisan (INN, USAN; development codes ZK-230211, BAY 86-5044, and ZK-PRA) is a synthetic, steroidal antiprogestogen which was under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis, dysmenorrhea, and breast cancer but was discontinued. It is a potent and highly selective silent antagonist of the progesterone receptor (PR). The drug reached phase II clinical trials prior to its discontinuation.
See also Mifepristone Onapristone Ulipristal acetate Vilaprisan
References
External links "Lonaprisan". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on January 16, 2020.


